Timothy D Murtha1, Taylor C Brown1, Jill C Rubinstein1, Felix Haglund2, C Christofer Juhlin2, Catharina Larsson2, Reju Korah1, Tobias Carling3. 1. Yale Department of Surgery & Yale Endocrine Neoplasia Laboratory, Yale School of Medicine, New Haven, CT. 2. Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. 3. Yale Department of Surgery & Yale Endocrine Neoplasia Laboratory, Yale School of Medicine, New Haven, CT. Electronic address: tobias.carling@yale.edu.
Abstract
BACKGROUND: Cytochrome P450-mediated metabolism of chemotherapeutic agents contributes to chemotherapy resistance in multiple malignancies. Adrenocortical carcinoma is known to have a poor response to adjuvant therapies; however, the mechanism remains unknown. Recent comprehensive genetic analyses of adrenocortical carcinomas demonstrated recurrent copy number gains in multiple cytochrome P450 genes prompting investigation into whether cytochrome P450 overexpression potentiates adrenocortical carcinoma chemoresistance. METHODS: We determined the expression patterns of 6 cytochrome P450 genes (CYP2A6, CYP2A7, CYP2A13, CYP2B6, CYP2S1, and CYP4F2) predicted to be amplified in adrenocortical carcinoma (n = 29) relative to normal adrenal cortex (n = 10). Gene copy numbers were determined with the TaqMan copy number assay. Gene silencing was performed via small interfering RNA (siRNA) in the adrenocortical carcinoma cell line NCI-H295R and treated with mitotane and cisplatin. RESULTS: Of the 6 cytochrome P450 genes tested, CYP2A6 was overexpressed with a 55-fold mean increase compared to normal adrenal samples (P < .05). Immunohistochemical analysis confirmed protein overexpression. Copy gains of CYP2A6 were found in 26% (7/27) of adrenocortical carcinoma specimens. Silencing of CYP2A6 in NCI-H295R cells resulted in decreased cell viability and increased chemosensitivity (P < .05). CONCLUSION: Frequent upregulation in adrenocortical carcinomas and the reversal of chemoresistance in adrenocortical carcinoma cells via enforced silencing suggest a role for CYP2A6 in adrenocortical malignancy.
BACKGROUND:Cytochrome P450-mediated metabolism of chemotherapeutic agents contributes to chemotherapy resistance in multiple malignancies. Adrenocortical carcinoma is known to have a poor response to adjuvant therapies; however, the mechanism remains unknown. Recent comprehensive genetic analyses of adrenocortical carcinomas demonstrated recurrent copy number gains in multiple cytochrome P450 genes prompting investigation into whether cytochrome P450 overexpression potentiates adrenocortical carcinoma chemoresistance. METHODS: We determined the expression patterns of 6 cytochrome P450 genes (CYP2A6, CYP2A7, CYP2A13, CYP2B6, CYP2S1, and CYP4F2) predicted to be amplified in adrenocortical carcinoma (n = 29) relative to normal adrenal cortex (n = 10). Gene copy numbers were determined with the TaqMan copy number assay. Gene silencing was performed via small interfering RNA (siRNA) in the adrenocortical carcinoma cell line NCI-H295R and treated with mitotane and cisplatin. RESULTS: Of the 6 cytochrome P450 genes tested, CYP2A6 was overexpressed with a 55-fold mean increase compared to normal adrenal samples (P < .05). Immunohistochemical analysis confirmed protein overexpression. Copy gains of CYP2A6 were found in 26% (7/27) of adrenocortical carcinoma specimens. Silencing of CYP2A6 in NCI-H295R cells resulted in decreased cell viability and increased chemosensitivity (P < .05). CONCLUSION: Frequent upregulation in adrenocortical carcinomas and the reversal of chemoresistance in adrenocortical carcinoma cells via enforced silencing suggest a role for CYP2A6 in adrenocortical malignancy.
Authors: Silviu Sbiera; Ellen Leich; Gerhard Liebisch; Iuliu Sbiera; Andreas Schirbel; Laura Wiemer; Silke Matysik; Carolin Eckhardt; Felix Gardill; Annemarie Gehl; Sabine Kendl; Isabel Weigand; Margarita Bala; Cristina L Ronchi; Timo Deutschbein; Gerd Schmitz; Andreas Rosenwald; Bruno Allolio; Martin Fassnacht; Matthias Kroiss Journal: Endocrinology Date: 2015-08-25 Impact factor: 4.736
Authors: Jill C Rubinstein; Taylor C Brown; Gerald Goh; C Christofer Juhlin; Adam Stenman; Reju Korah; Tobias Carling Journal: Surgery Date: 2015-10-06 Impact factor: 3.982
Authors: Ankit V Gandhi; Shivam Saxena; Daniel Relles; Konrad Sarosiek; Christopher Y Kang; Galina Chipitsyna; Jocelyn Andrel Sendecki; Charles J Yeo; Hwyda A Arafat Journal: Ann Surg Oncol Date: 2013-07-12 Impact factor: 5.344
Authors: N P Lang; M A Butler; J Massengill; M Lawson; R C Stotts; M Hauer-Jensen; F F Kadlubar Journal: Cancer Epidemiol Biomarkers Prev Date: 1994-12 Impact factor: 4.254
Authors: C Christofer Juhlin; Adam Stenman; Felix Haglund; Victoria E Clark; Taylor C Brown; Jacob Baranoski; Kaya Bilguvar; Gerald Goh; Jenny Welander; Fredrika Svahn; Jill C Rubinstein; Stefano Caramuta; Katsuhito Yasuno; Murat Günel; Martin Bäckdahl; Oliver Gimm; Peter Söderkvist; Manju L Prasad; Reju Korah; Richard P Lifton; Tobias Carling Journal: Genes Chromosomes Cancer Date: 2015-05-29 Impact factor: 5.006
Authors: Reju Korah; James M Healy; John W Kunstman; Annabelle L Fonseca; Amir H Ameri; Manju L Prasad; Tobias Carling Journal: Mol Cancer Date: 2013-08-05 Impact factor: 27.401